Medicare Enrolled

Dr. Radhakrishnan Ramchandren, MD

Independent Medical Examiner Physician · West Reading, PA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
420 S 5TH AVE BLDG N, West Reading, PA 19611
4846280900
In practice since 2007 (19 years)
NPI: 1700089331 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ramchandren from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ramchandren? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Ramchandren

Dr. Radhakrishnan Ramchandren is an independent medical examiner physician in West Reading, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ramchandren performed 563 Medicare services across 183 unique beneficiaries.

Between the years covered by Open Payments, Dr. Ramchandren received a total of $236,463 from 69 pharmaceutical and/or device companies across 445 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in independent medical examiner physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Ramchandren is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ 563 Medicare services $236,463 industry payments

Medicare Practice Summary

Medicare Utilization ↗
563
Medicare services
1.0× state median for independent medical examiner physician
183
Unique beneficiaries
$81
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~30 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
346 $68 $301
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
147 $90 $240
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
55 $129 $470
New patient office visit, complex (60-74 min) 15 $133 $512
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$236,463
Total received (2018-2024)
Avg $33,780/year across 7 years
Top 0% in PA for independent medical examiner physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
445
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$108,197 (45.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$106,304 (45.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,962 (9.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$65,746
2023
$43,715
2022
$25,216
2021
$9,489
2020
$28,226
2019
$20,200
2018
$43,871

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$51,106
SOBI, INC
$9,353
E.R. Squibb & Sons, L.L.C.
$2,796
Daiichi Sankyo Inc.
$1,983
PFIZER INC.
$49
GENZYME CORPORATION
$47
Janssen Biotech, Inc.
$43
ABBVIE INC.
$41
Genentech USA, Inc.
$34
Celgene Corporation
$31
Regeneron Healthcare Solutions, Inc.
$27
Rigel Pharmaceuticals, Inc.
$26
Takeda Pharmaceuticals U.S.A., Inc.
$25
Kite Pharma, Inc.
$25
EMD Serono, Inc.
$21
Karyopharm Therapeutics Inc.
$21
Astellas Pharma US Inc
$20
Blueprint Medicines Corporation
$19
Adaptive Biotechnologies Corporation
$17
AstraZeneca Pharmaceuticals LP
$17
Acrotech Biopharma Inc.
$17
Novartis Pharmaceuticals Corporation
$15
Pharmacosmos Therapeutics Inc.
$14
Top 3 companies account for 96.2% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$53,300
Seagen Inc.
$32,671
Celgene Corporation
$23,004
Merck Sharp & Dohme LLC
$20,692
E.R. Squibb & Sons, L.L.C.
$16,408
ADC Therapeutics America, Inc.
$12,245
Sandoz Inc.
$9,541
SOBI, INC
$9,353
Seattle Genetics, Inc.
$9,344
Merck Sharp & Dohme Corporation
$7,260
PFIZER INC.
$5,796
Incyte Corporation
$5,656
AstraZeneca Pharmaceuticals LP
$4,446
Daiichi Sankyo Inc.
$4,015
Pharmacyclics LLC, An AbbVie Company
$3,620
JAZZ PHARMACEUTICALS INC.
$3,373
Ipsen Biopharmaceuticals, Inc
$2,751
Kite Pharma, Inc.
$2,227
Gilead Sciences, Inc.
$2,122
Karyopharm Therapeutics Inc.
$1,977
Janssen Scientific Affairs, LLC
$1,515
Hoffmann-La Roche Limited
$1,320
F. Hoffmann-La Roche AG
$553
Genentech USA, Inc.
$466
Novartis Pharmaceuticals Corporation
$322
Genentech, Inc.
$245
Amgen Inc.
$240
Epizyme, Inc.
$165
Janssen Biotech, Inc.
$144
Regeneron Healthcare Solutions, Inc.
$137
GENZYME CORPORATION
$134
Takeda Pharmaceuticals U.S.A., Inc.
$118
Lilly USA, LLC
$102
ABBVIE INC.
$82
Astellas Pharma US Inc
$78
BeiGene USA, Inc.
$65
Rigel Pharmaceuticals, Inc.
$56
Alexion Pharmaceuticals, Inc.
$56
EMD Serono, Inc.
$55
Genmab U.S., Inc.
$50
Eisai Inc.
$46
EISAI INC.
$45
Bayer HealthCare Pharmaceuticals Inc.
$41
Acrotech Biopharma Inc.
$37
Blueprint Medicines Corporation
$35
Jazz Pharmaceuticals Inc.
$33
TG THERAPEUTICS, INC.
$33
Alnylam Pharmaceuticals Inc.
$33
Adaptive Biotechnologies Corporation
$32
Agios Pharmaceuticals, Inc.
$31
MorphoSys, US Inc.
$31
Exelixis Inc.
$30
Deciphera Pharmaceuticals Inc.
$30
Mirati Therapeutics, Inc.
$29
PUMA BIOTECHNOLOGY, INC.
$29
Pharmacosmos Therapeutics Inc.
$29
MACROGENICS, INC.
$23
Sun Pharmaceutical Industries Inc.
$20
AVEO Pharmaceuticals, Inc.
$20
Acceleron Pharma, Inc.
$19
Pharming Healthcare, Inc.
$18
ARRAY BIOPHARMA INC
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
TAIHO ONCOLOGY, INC.
$14
Pharmacyclics LLC, an AbbVie Company
$14
Aadi Bioscience, Inc.
$14
Myriad Genetic Laboratories, Inc.
$14
Kyowa Kirin, Inc.
$13
Taiho Oncology, Inc.
$12
Top 3 companies account for 46.1% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ALUNBRIG · AMVUTTRA · AYVAKIT · Alecensa · Avastin · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CALQUENCE · CYRAMZA · Cabometyx · Cresemba · DARZALEX · ELIQUIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · Enhertu · Epkinly · FOTIVDA · Fyarro · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JCAR017 · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · KYMRIAH · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MARGENZA · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Non-Covered Product · Nplate · Nubeqa · OJJAARA · ONPATTRO · ONUREG · OPDIVO · Odomzo · PADCEV · PEMAZYRE · POTELIGEO · PROMACTA · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RUCONEST · RYBREVANT · Reblozyl · Revlimid · Rezlidhia · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · Stivarga · TAGRISSO · TEPMETKO · TIBSOVO · TUKYSA · Tavalisse · Tazverik · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VYNDAQEL · VYXEOS · Vanflyta · Venclexta · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEPZELCA · Zydelig · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (46%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in independent medical examiner physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for independent medical examiner physician in PA.

Looking for an independent medical examiner physician in West Reading?
Compare independent medical examiner physicians in the West Reading area by procedure volume, costs, and industry payment transparency.
Browse independent medical examiner physicians nearby

Geographic Context

Independent medical examiner physicians within 10 mi
1
Per 100K population
0.2
County median income
$77,684
Nearest hospital
READING HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Ramchandren is a clinical cardiology specialist, with speaking/promotional industry engagement in the top 0% of PA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Ramchandren experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Ramchandren performed 346 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ramchandren receive payments from pharmaceutical companies?
Yes. Dr. Ramchandren received a total of $236,463 from 69 companies across 445 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ramchandren's costs compare to other independent medical examiner physicians in West Reading?
Dr. Ramchandren's average Medicare payment per service is $81. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ramchandren) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →